MetaCap

Perrigo (PRGO) vs Xencor (XNCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xencor (XNCR) has outperformed Perrigo (PRGO) over the past year, gaining 109.6% versus a gain of 26.1%. Over five years, XNCR leads with a -6.2% price change compared with -57.8% for PRGO. Xencor is the larger company by market cap ($2.50 billion vs $2.21 billion), about 1.1 times the size.

Perrigo pays a dividend yielding 7.28%, while Xencor does not currently pay one. Perrigo converts more of its revenue into profit, with a net margin of -33.5% versus -73.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PRGO+26.11%XNCR+109.58%
+161%+59%-44%
Nov 21, 20251 yearNov 20, 2026
PRGO-61.25%XNCR-9.77%
+15%-35%-85%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PRGO versus XNCR key metrics
MetricPRGOXNCR
Share price$15.94$33.26
Market cap$2.21B$2.50B
1-day change-0.62%-2.21%
YTD return+14.51%+117.24%
1-year return+26.11%+109.58%
5-year return-57.81%-6.15%
Forward P/E6.94—
EPS (TTM)$-12.47$-1.56
Dividend yield7.28%0.00%
Annual dividend$1.16$0.00
Revenue (latest FY)$4.25B$125.58M
Revenue growth (YoY)-2.75%+13.65%
Net income (latest FY)$-1.43B$-91.92M
Gross margin35.14%—
Operating margin-26.39%-141.35%
Net margin-33.51%-73.20%
52-week high$17.07$40.60
52-week low$9.23$10.38
Distance from 52-week high-6.62%-18.08%
Analyst consensusbuystrong_buy
Avg. price target upside+12.92%+27.78%
Average volume2.54M1.54M
Shares outstanding138.80M75.04M
Employees8,100260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XNCR has outperformed PRGO by 83.5 percentage points over the past year.
  • Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
  • Perrigo is more profitable, keeping -33.5 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
  • Xencor grew revenue faster in its latest fiscal year (+13.65% vs -2.75%).

About Perrigo

PRGO stock →

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees

About Xencor

XNCR stock →

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

PRGO vs XNCR FAQ

Which is bigger, Perrigo or Xencor?

Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.21B for Perrigo (PRGO).

Which stock has performed better over the past year, PRGO or XNCR?

XNCR returned +109.58% over the past 12 months, compared with +26.11% for PRGO (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Perrigo or Xencor?

Perrigo pays a dividend yielding 7.28%, while Xencor does not currently pay a regular dividend.

Are Perrigo and Xencor in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons